Ropes & Gray Advised Genstar Capital and Flourish Research in Partnership with Valkyrie Clinical Trials

Ropes & Gray represented Genstar Capital and its portfolio company Flourish Research in a partnership with Valkyrie Clinical Trials, a premier network of oncology-focused clinical research sites. The partnership was announced on October 6, 2025, in a press release.

Genstar Capital is a leading private equity firm that has been actively investing in high-quality companies for over 30 years. Based in San Francisco, Genstar works in partnership with its management teams and its network of strategic advisors to transform its portfolio companies into industry-leading businesses. Genstar currently has approximately $50 billion of assets under management and targets investments focused on targeted segments of the financial services, software, healthcare, and industrials industries.

Flourish is a leading multi-site clinical trial organization focused primarily on cardiovascular, metabolic, neuroscience, and infectious disease therapeutic areas. Headquartered in Apex, NC, Flourish's network of 30 sites and over 160 investigators conducts studies spanning all phases of clinical trial research.

The deal team was led by private equity partner Chau Le and included tax partner Brandon Dunn, health care partner David Peloquin, employment partners Megan Bisk and Doug Brayley, IP transactions partner Emily Karlberg, life sciences regulatory & compliance partner Josh Oyster, executive compensation & employee benefits partner Kyle Higley, antitrust partner Jackie Grise Lester, real estate partner Sally Davis, environmental partner Peter Alpert, data, privacy & cybersecurity partner Fran Faircloth, and private equity associate Anna Park.